Takami Sato, MD, Ph.D
Philadelphia, PA 19107
Most Recent Peer-reviewed Publications
- Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma
- Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases
- Biology of advanced uveal melanoma and next steps for clinical therapeutics
- Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
- Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity
Jichi Medical University, Japan - 1980
Oita Prefectural Hospital, Japan
Jichi Medical University, Japan
Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital
Active Medical Staff
Director, Metastatic Uveal Melanoma Program
K. Hasumi Endowed Professor of Medical Oncology
Research and Clinical Interests
Medical Oncology, Melanoma, Skin Cancer, Uveal Melanoma, Ocular Melanoma, Cancer Immunotherapy
As director of the Metastatic Uveal Melanoma Program at Jefferson, Dr. Sato heads one of the few programs in the United States treating melanoma originating in the eye. Although uveal melanoma is the most common adult eye tumor, the disease is very rare, affecting only six or seven people per one million. This cancer commonly spreads to the liver, and patients who do not receive treatment live an average of six months. Dr. Sato has devoted his career to improving understanding of this disease and developing new treatments, particularly for patients who are not eligible for surgery.
Dr. Sato’s studies focus on cancer immunotherapy, or the use of the immune system to fight cancer. His clinical trials involving a procedure called immunoembolization have shown promising results.
In immunoembolization, a chemical to stimulate patients’ immune systems is administered to the hepatic artery that feeds the liver tumor and then the artery is blocked, cutting off oxygen to tumors and keeping the injected medicine in the tumor. In one trial, one-third of patients had tumor shrinkage, and another third experienced no tumor growth. Dr. Sato is building on these outcomes as he continues to examine methods of treating uveal melanoma and delaying its progression.